No significant difference was noted between the SMART and standard groups in the proportion of participants with at least one high-use episode of agonist ( 84 [ 56 % ] vs 68 [ 45 % ] , respectively , relative risk 124 [ 95 % CI 099-156 ] ; p = 0058 ) .